Company Valuation: Cardiol Therapeutics Inc.

Data adjusted to current consolidation scope
Fiscal Period: December 2021 2022 2023 2024 2025 2026 2027 2028
Market Cap 1 142 43.96 71.77 151 130.4 171.8 - -
Change - -69.05% 63.28% 110.34% -13.65% 31.75% - -
Enterprise Value (EV) 1 142 43.96 36.84 120.4 108.9 156.7 161.5 171.8
Change - -69.05% -16.19% 226.78% -9.5% 43.88% 3.03% 6.35%
P/E -3.19x -1.41x -2.5x -3.63x -3.36x -4.14x -6.41x 40.6x
PBR - - 2.55x 6.18x 6.41x 8.47x 15.5x -
PEG - 0x 0.2x -0.2x 0.1x 0.54x 0.2x -0x
Capitalization / Revenue 1,803x - - - - - 51.7x 4.73x
EV / Revenue 1,803x - - - - - 48.6x 4.73x
EV / EBITDA -4.74x -1.07x -1.25x -3x -3.18x -6.66x -10.2x -8.33x
EV / EBIT -3.67x -1.06x -1.24x -2.99x -3.17x -4.47x -6.01x 35.6x
EV / FCF -6.03x - -1.46x -4.8x -4.56x -7.72x -34.5x -
FCF Yield -16.6% - -68.5% -20.8% -21.9% -13% -2.9% -
Dividend per Share 2 - - - - - - - -
Rate of return - - - - - - - -
EPS 2 -0.73 -0.49 -0.44 -0.51 -0.39 -0.36 -0.2325 0.0367
Distribution rate - - - - - - - -
Net sales 1 0.0788 - - - - - 3.321 36.32
EBITDA 1 -29.95 -41.12 -29.54 -40.11 -34.21 -23.54 -15.88 -20.62
EBIT 1 -38.66 -41.34 -29.79 -40.28 -34.32 -35.09 -26.87 4.821
Net income 1 -31.64 -30.93 -28.13 -36.68 -33.82 -35.21 -30.57 -8.68
Net Debt 1 - - -34.93 -30.58 -21.42 -15.01 -10.26 -
Reference price 2 2.330 0.690 1.100 1.850 1.310 1.490 1.490 1.490
Nbr of stocks (in thousands) 60,954 63,703 65,247 81,603 99,514 115,272 - -
Announcement Date 23/03/22 28/03/23 01/04/24 31/03/25 31/03/26 - - -
1CAD in Million2CAD
Estimates

P/E, Detailed evolution

P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
-4.14x - -6.66x - 121M
31.89x5.62x17.4x1.03% 45.45B
-21.35x318.3x-19.6x-.--% 36.09B
41.34x4.13x26.44x-.--% 30.81B
22.59x2.58x11.16x-.--% 30.98B
29.08x7.52x19.35x0.43% 24.62B
30.09x4.86x22.13x-.--% 14.65B
23.27x1.99x8.76x1.15% 13.3B
-21.35x13.92x-20.8x-.--% 12.65B
Average 14.60x 44.86x 6.46x 0.33% 23.18B
Weighted average by Cap. 18.44x 59.51x 9.09x 0.35%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Stocks
  3. CRDL Stock
  4. Valuation Cardiol Therapeutics Inc.